Sorafenib and Regorafenib are two small molecule multi‐kinase inhibitors that have been reported to inhibit the progression of osteosarcoma.[17] Sorafenib inhibits the activity of both electron transport chain and ATP synthase to activate the PINK1/Parkin pathway.[18] Sorafenib and Regorafenib were ranked among the top 20 hits in our kinase inhibitor screening (Figure 5b and Figure S5a, Supporting Information). The gene discussed is PRKN; the disease is osteosarcoma.